Nestlé S.A. (SWX:NESN) is discussing a potential sale of its peanut allergy medicine to Swiss health-care group Stallergenes Greer Ltd, people with knowledge of the matter said. Stallergenes has been holding talks with Nestlé about a possible deal for the Palforzia treatment, the people said, asking not to be identified discussing confidential information.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | +0.14% | +29.68% |
2023 | Nestle Reportedly May Sell Peanut Allergy Therapy to Stallergenes | CI |
2023 | Stallergenes Greer Ltd Initiates European Paediatric Phase III Study with Staloral Birch | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
91.72 CHF | -0.11% | -1.06% | 266B | ||
- EUR | -.--% | +0.14% | 0 | ||
1st Jan change | Capi. | |
---|---|---|
+29.68% | 0 | |
+5.48% | 71.19B | |
+12.55% | 9.3B | |
-13.75% | 5.01B | |
+42.38% | 4.47B | |
+4.51% | 3.96B | |
+21.10% | 2.44B | |
-19.05% | 2.41B | |
-28.72% | 2.23B | |
+11.13% | 2.02B |
- Stock Market
- Equities
- STAGR Stock
- News Stallergenes Greer
- Nestle Reportedly May Sell Peanut Allergy Therapy to Stallergenes